Population pharmacokinetics of fentanyl in the critically Ill

Critical Care Medicine

Volumn 44, Issue 1, 2016, Pages 64-72

  Choi, Leena ^a   Ferrell, Benjamin A ^b   Vasilevskis, Eduard E ^b,c   Pandharipande, Pratik P ^b,c   Heltsley, Rebecca ^d   Ely, E Wesley ^b,c   Stein, C Michael ^b   Girard, Timothy D ^b,c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Aegis Sciences Corporation   (United States)

Author keywords

fentanyl; intensive care; mechanical ventilation; pharmacokinetics; sedation

Indexed keywords

FENTANYL; NARCOTIC ANALGESIC AGENT;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTINUOUS INFUSION; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; FEMALE; HUMAN; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; VOLUME OF DISTRIBUTION; BLOOD; MIDDLE AGED; THEORETICAL MODEL; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; CRITICAL CARE; CRITICAL ILLNESS; FEMALE; FENTANYL; HUMANS; MALE; MIDDLE AGED; MODELS, THEORETICAL; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84983182101     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000001347     Document Type: Article

References (39)

1. Payen JF, Chanques G, Mantz J, Current practices in sedation and analgesia for mechanically ventilated critically ill patients: A prospective multicenter patient-based study. Anesthesiology 2007 106 687 695. quiz 891
2. Barr J, Fraser GL, Puntillo K, American College of Critical Care Medicine Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med 2013 41 263 306
3. Girard TD, Kress JP, Fuchs BD, Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): A randomised controlled trial. Lancet 2008 371 126 134
4. Shehabi Y, Bellomo R, Reade MC, Sedation Practice in Intensive Care Evaluation (SPICE) Study Investigators; ANZICS Clinical Trials Group Early intensive care sedation predicts long-term mortality in ventilated critically ill patients. Am J Respir Crit Care Med 2012 186 724 731
5. Feierman DE, Lasker JM, Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4. Drug Metab Dispos 1996 24 932 939
6. Greenblatt DJ, Harmatz JS, Shader RI, Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Therapeutic considerations (Part II). Clin Pharmacokinet 1991 21 262 273
7. Ariano RE, Duke PC, Sitar DS, Population pharmacokinetics of fentanyl in healthy volunteers. J Clin Pharmacol 2001 41 757 763
8. Kaneda K, Han TH, Comparative population pharmacokinetics of fentanyl using non-linear mixed effect modeling: Burns vs. Non-burns. Burns 2009 35 790 797
9. Hudson RJ, Thomson IR, Henderson BT, Validation of fentanyl pharmacokinetics in patients undergoing coronary artery bypass grafting. Can J Anaesth 2002 49 388 392
10. Jin SJ, Jung JY, Noh MH, The population pharmacokinetics of fentanyl in patients undergoing living-donor liver transplantation. Clin Pharmacol Ther 2011 90 423 431
11. Pandharipande PP, Girard TD, Jackson JC, BRAIN-ICU Study Investigators Long-term cognitive impairment after critical illness. N Engl J Med 2013 369 1306 1316
12. Depriest A, Heltsley R, Black DL, Urine drug testing of chronic pain patients. III Normetabolites as biomarkers of synthetic opioid use. J Anal Toxicol 2010 34 444 449
13. Heltsley R, DePriest A, Black DL, Oral fluid drug testing of chronic pain patients. I. Positive prevalence rates of licit and illicit drugs. J Anal Toxicol 2011 35 529 540
14. Beal SL, Sheiner LB, Boeckmann A, NONMEM User's Guides 2009 Ellicott City, MD Icon Development Solutions
15. Charlson ME, Pompei P, Ales KL, A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987 40 373 383
16. Deyo RA, Cherkin DC, Ciol MA, Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992 45 613 619
17. Knaus WA, Draper EA, Wagner DP, APACHE II: A severity of disease classification system. Crit Care Med 1985 13 818 829
18. Vincent JL, Moreno R, Takala J, The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996 22 707 710
19. U. S. Food and Drug Administration: Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm. Accessed June 22, 2015
20. Kim JH, Estimating classification error rate: Repeated cross-validation, repeated hold-out and bootstrap. Comput Stat Data An 2009 53 3735 3745
21. Molinaro AM, Simon R, Pfeiffer RM, Prediction error estimation: A comparison of resampling methods. Bioinformatics 2005 21 3301 3307
22. R Core Team: R: A Language and Environment for Statistical Computing 2014 Vienna, Austria R Foundation for Statistical Computing
23. Välitalo PA, Ahtola-Sätilä T, Wighton A, Population pharmacokinetics of dexmedetomidine in critically ill patients. Clin Drug Investig 2013 33 579 587
24. Bailie GR, Cockshott ID, Douglas EJ, Pharmacokinetics of propofol during and after long-term continuous infusion for maintenance of sedation in ICU patients. Br J Anaesth 1992 68 486 491
25. Swart EL, Zuideveld KP, de Jongh J, Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. Br J Clin Pharmacol 2004 57 135 145
26. Kohli U, Pandharipande P, Muszkat M, CYP2A6 genetic variation and dexmedetomidine disposition. Eur J Clin Pharmacol 2012 68 937 942
27. Choi L, Caffo BS, Kohli U, A Bayesian hierarchical nonlinear mixture model in the presence of artifactual outliers in a population pharmacokinetic study. J Pharmacokinet Pharmacodyn 2011 38 613 636
28. Casati A, Putzu M, Anesthesia in the obese patient: Pharmacokinetic considerations. J Clin Anesth 2005 17 134 145
29. Shibutani K, Inchiosa MA Jr, Sawada K, Accuracy of pharmacokinetic models for predicting plasma fentanyl concentrations in lean and obese surgical patients: Derivation of dosing weight ("pharmacokinetic mass"). Anesthesiology 2004 101 603 613
30. Bower S, Hull CJ, Comparative pharmacokinetics of fentanyl and alfentanil. Br J Anaesth 1982 54 871 877
31. Haberer JP, Schoeffler P, Couderc E, Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis. Br J Anaesth 1982 54 1267 1270
32. Bosilkovska M, Walder B, Besson M, Analgesics in patients with hepatic impairment: Pharmacology and clinical implications. Drugs 2012 72 1645 1669
33. McClain DA, Hug CC Jr, Intravenous fentanyl kinetics. Clin Pharmacol Ther 1980 28 106 114
34. Scott JC, Stanski DR, Decreased fentanyl and alfentanil dose requirements with age. A simultaneous pharmacokinetic and pharmacodynamic evaluation. J Pharmacol Exp Ther 1987 240 159 166
35. Shafer SL, Varvel JR, Aziz N, Pharmacokinetics of fentanyl administered by computer-controlled infusion pump. Anesthesiology 1990 73 1091 1102
36. Singleton MA, Rosen JI, Fisher DM, Pharmacokinetics of fentanyl in the elderly. Br J Anaesth 1988 60 619 622
37. Niscola P, Scaramucci L, Vischini G, The use of major analgesics in patients with renal dysfunction. Curr Drug Targets 2010 11 752 758
38. Mercadante S, Arcuri E, Opioids and renal function. J Pain 2004 5 2 19
39. Hamburg MA, Collins FS, The path to personalized medicine. N Engl J Med 2010 363 301 304